Pfizer and Moderna Stocks: Down 30% and 27% – Buy and Hold

Pfizer and Moderna: Navigating Post-Pandemic Challenges and Opportunities

In the fierce battle against COVID-19, two pharmaceutical giants, Pfizer and Moderna, emerged as frontrunners, dominating the vaccine market. The unprecedented demand for their vaccines translated into soaring revenues, earnings, and share prices. However, as the pandemic's intensity waned, both companies faced market corrections. Amidst this decline, the strategic moves and product pipelines of Pfizer and Moderna merit a closer examination, revealing potential avenues for future growth.